Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2019

01-09-2019 | Sitagliptin | Debate

Use of Insulin in the Inpatient Setting: Need for Continued Use

Authors: Smita Kumar, Mark E. Molitch

Published in: Current Diabetes Reports | Issue 9/2019

Login to get access

Abstract

Purpose of Review

Insulin has been the standard of care for the management of inpatient diabetes for achieving strict glycemic control. This review supports continuing insulin therapy for hyperglycemic management in the hospital compared with the use of non-insulin treatment regimens.

Recent Findings

Oral hypoglycemic agents and glucagon-like peptide 1 (GLP-1) receptor agonists have typically not been used in the inpatient setting. Recent studies regarding DPP-4 inhibitors have led to variable results with fairly high glycemic values during the hospitalization. Similarly, studies looking at GLP-1 receptor agonists are limited, but gastrointestinal side effects limit their inpatient use.

Summary

Overall, there is a paucity of data to support the use of non-insulin-based therapy in the inpatient setting. Insulin has repeatedly demonstrated that its advantageous quality of being easily titratable leads to more consistently efficacious glycemic control that improves morbidity and mortality.
Literature
1.
• Umpierrez G, Isaacs S, Bazargan N, You X, Thaler L, Kitabchi A. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978–82 This was one the first articles to stress the importance of hyperglycemia being an important contributor to inpatient mortality. CrossRef
2.
Davis G, Fayfman M, Reyes-Umpierrez D, Hafeez S, Pasquel FJ, Vellanki P, et al. Stress hyperglycemia in general surgery: why should we care? J Diab Compl. 2018;32(3):305–9.CrossRef
3.
•• Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67 This study triggered the need for better inpatient glycemic control to reduce surgical complications. CrossRef
4.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. for the NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360(13):1283–1297.
5.
Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groenveld J, et al. Prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35(10):1738–48.CrossRef
6.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.CrossRef
7.
Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults. A meta-analysis JAMA. 2008;300:933–44.PubMed
8.
Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.CrossRef
9.
American Diabetes Association. Diabetes care in the hospital. Section. 15. In Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S173-S181.
10.
Weintraub WS, Wenger NK, Jones EL, Craver JM, Guyton RA. Changing clinical characteristics of coronary surgery patients. Differences between men and women. Circulation. 1993;88:78–86.
11.
Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67:352–60.CrossRef
12.
Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones EL, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999;67:1045–52.CrossRef
13.
Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78:1471–8.CrossRef
14.
Furnary A, Wu Y, Bookin S. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland diabetic project. Endocr Pract. 2004;10:21–33.CrossRef
15.
DeSantis AJ, Schmeltz LR, Schmidt K, O’Shea-Mahler E, Rhee C, Wells A, et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract. 2006;12:491–505.CrossRef
16.
Schmeltz L, DeSantis A, Thiyagarajan V, Schmidt K, O’Shea-Mahler E, Johnson D, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care. 2007;30:823–8.CrossRef
17.
Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497–502.CrossRef
18.
Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care. 2015;38(9):1665–72.CrossRef
19.
Wallia A, Parikh ND, O’Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, et al. Glycemic control by a glucose management service and infection rates following liver transplantation. Endocr Pract. 2011;16:1–21.
20.
Wallia A, Schmidt K, Johnson Oakes D, Pollack T, Welsh N, Kling-Colson A, et al. Glycemic control reduces post-transplant infections in liver transplant patients: results of a prospective, randomized, study. J Clin Endocrinol Metab. 2017;102(2):451–9.PubMed
21.
Gandhi GY, Murad MH, Flynn DN, Erwin PJ, Cavalcante AB, Nielsen HB, et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clin Proc. 2008;83:418–30.CrossRef
22.
• Sathya B, Davis R, Taveira T, Whitlatch H, Wu WC. Intensity of perioperative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013;102:8–15 This recent meta-analysis confirmed the benefits of insulin-intensive therapy in reducing inpatient mortality. CrossRef
23.
Mulla I, Schmidt K, Cashy J, Wallia A, Andrei A-C, Oakes DJ, et al. Comparison of glycemic and surgical outcomes after change in glycemic targets in cardiac surgery patients. Diabetes Care. 2014;37:2960–5.CrossRef
24.
Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6.CrossRef
25.
Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–61.CrossRef
26.
Hansen T, Thiel S, Wouters P, Christiansen J, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082–8.CrossRef
27.
Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187–95.CrossRef
28.
Bakris GL, Molitch ME. Should restrictions be relaxed for metformin use in chronic kidney disease? Yes, they should be relaxed! What’s the fuss? Diabetes Care. 2016;39(7):1287–91.CrossRef
29.
Umpierrez G, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.CrossRef
30.
Brackbill M, Rahman A, Sandy J, Stam M, Harralson A. Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study. Int J Endocrinol. 2012;2012:1–6.CrossRef
31.
Fayfman M, Davis G, Duggan EW, Urrutia M, Chachkhiani D, Schindler J, et al. Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: a pilot randomized study. J Diab Compl. 2018;32(12):1091–6.CrossRef
32.
Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33.CrossRef
33.
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicenter randomized clinical trial. Diabetes Obes Metab. 2018.
34.
Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5(1):e000394.CrossRef
35.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRef
36.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRef
37.
Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36(7):2112–7.CrossRef
38.
Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2019;42(3):450–5.CrossRef
39.
Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019.
40.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRef
41.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J M. 2016;375(4):323–34.CrossRef
42.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.CrossRef
43.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A and the DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380(4):347–357.
44.
Lupsa BC, Inzuchhi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118–25.CrossRef
45.
Gianchandani RY, Pasquel FJ, Rubin DJ, Dungan KM, Vellanki P, Wang H, et al. The efficacy and safety of co-administration of sitagliptin with metformin in patients with type 2 diabetes at hospital discharge. Endocr Pract. 2018;24(6):556–64.CrossRef
46.
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701 This consensus statement emphasized the cardiovascular and kidney benefits of GLP-1 receptor agonists and SLGT2 inhibitors in the management of patients with type 2 diabetes who have underlying cardiovascular or kidney disease. CrossRef
47.
American Diabetes Association. Pharmacologic approaches to glycemic treatment. Section. 9. In Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S90-S102.
Metadata
Title
Use of Insulin in the Inpatient Setting: Need for Continued Use
Authors
Smita Kumar
Mark E. Molitch
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1183-9

Other articles of this Issue 9/2019

Current Diabetes Reports 9/2019 Go to the issue

Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Economics of Beta-Cell Replacement Therapy

Psychosocial Aspects (SS Jaser, Section Editor)

Can the Routine Use of Patient-Reported Outcome Measures Improve the Delivery of Person-Centered Diabetes Care? A Review of Recent Developments and a Case Study

Pathogenesis of Type 2 Diabetes and Insulin Resistance (M-E Patti, Section Editor)

Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes

Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)

Liver to Pancreas Transdifferentiation

Diabetes and Pregnancy (M-F Hivert and CE Powe, Section Editors)

Nutritional Supplementation for the Prevention and/or Treatment of Gestational Diabetes Mellitus

Microvascular Complications—Retinopathy (DL Chao and G Yiu, Section Editors)

Scaling Up Teleophthalmology for Diabetic Eye Screening: Opportunities for Widespread Implementation in the USA
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits